MedChemExpress MCE - Products
MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use.
| Product | Description | |
|---|---|---|
| Bevacizumab | Bevacizumab, a humanized IgG1 monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity. Uses: Scientific research. Category: Signaling pathways. Alternative Names: Anti-Human VEGF, Humanized Antibody. CAS No. 216974-75-3. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-P9906. |  |
| Bevacizumab (Anti-VEGFA) | Bevacizumab, a humanized IgG1 monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity[1][2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 216974-75-3. Pack Sizes: 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-P9906A. | |
| Bevenopran | Bevenopran is a peripheral μ-opioid receptor antagonist[1][2]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: CB-5945; ADL-5945. CAS No. 676500-67-7. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-100122. | |
| Bevonescein | Bevonescein (ALM-488) is a fluorescein-conjugated peptide that facilitates the targeted delivery of a fluorescent moiety (5-FAM (HY-66022)) to nerves after intravenous (IV) administration. Bevonescein binds nerve-associated connective tissue, labels peripheral nerves under real-time fluorescence imaging (FL) in living mice and human ex vivo nerve tissue. Bevonescein is a peptide-linked tracer which fluorescently labeled both intact and degenerated nerves (Ex/Em = 480/530 nm)[1][2][3]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: ALM-488. CAS No. 2276787-79-0. Pack Sizes: 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-P4154. | |
| Bevurogant | Bevurogant (BI 730357) is a retinoid-related orphan receptor-gamma t (RORγt) antagonist. Bevurogant can be used for the research of chronic inflammatory diseases[1][2]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: BI 730357. CAS No. 1817773-66-2. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-132810. | |
| Bexarotene | Bexarotene (LGD1069) is a high-affinity and selective retinoid X receptors (RXR) agonist with EC50s of 33, 24, 25 nM for RXRα, RXRβ, and RXRγ, respectively. Bexarotene shows limited affinity for RAR receptors (EC50 >10000 nM)[1][2][3]. Bexarotene can be used for the research of cutaneous T-cell lymphoma. Uses: Scientific research. Category: Signaling pathways. Alternative Names: LGD1069. CAS No. 153559-49-0. Pack Sizes: 10 mM * 1 mL in DMSO; 50 mg; 100 mg; 250 mg; 500 mg; 1 g. Product ID: HY-14171. | |
| Bexicaserin | Bexicaserin (LP352) is a 5-HT2C receptor agonist with potential for studying obesity and psychiatric-related disorders (such as epilepsy)[1][2]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: LP352. CAS No. 2035818-24-5. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-156601. | |
| Bexmarilimab | Bexmarilimab (FP-1305) is a potent humanized anti-CLEVER-1 IgG4 antibody with an IC50 value of 4.51 nM. Bexmarilimab is capable of inducing a phenotypic M2 to M1 immune switch of tumor-associated macrophages. Bexmarilimab can promote antigen presentation and pro-inflammatory cytokine secretion. Bexmarilimab can induce B-cell and T-cell activation. Bexmarilimab can be used in researches of immunology and cancer, such as colorectal carcinoma[1][2]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: FP-1305. CAS No. 2259301-27-2. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-P99236. | |
| Bexobrutideg | Bexobrutideg (NX-5948) is an orally active chimeric targeting molecule (CTM) that induces specific BTK protein degradation by the cereblon E3 ligase (CRBN) complex without degradation of other cereblon neo-substrates. Bexobrutideg mediates potent anti-inflammatory activity via BTK degradation with resultant inhibition of B cell activation. Bexobrutideg exhibits potent tumor growth inhibition in TMD8 xenograft models that contain either wild-type BTK or BTKi-resistant mutations. Bexobrutideg is efficacious in a mouse collageninduced arthritis (CIA) model. Bexobrutideg can cross the blood brain barrier (BBB). Bexobrutideg is a PROTAC composed of the ligand for target protein, a linker, and a cereblon E3 ligase (CRBN) complex (Red: BTK ligand (HY-170324); Blue: CRBN ligand (HY-171893); Black: linker)[1][2][3]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: NX-5948; BTK-IN-24. CAS No. 2649400-34-8. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-153321. | |
| Bexotegrast | Bexotegrast (PLN-74809) is an orally active, potent dual αvβ6/αvβ1 integrin inhibitor with Kd of 5.7 nM and 3.4 nM, respectively. Bexotegrast inhibits αvβ6- and αvβ1-induced TGF-β activation with IC50 values of 29.8 nM and 19.2 nM, respectively. Bexotegrast has antifibrogenic effects and block multiple avenues of TGF-β activation in the fibrotic lung[1][2]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: PLN-74809. CAS No. 2376257-44-0. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-137561. | |
| Bezafibrate | Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent. Uses: Scientific research. Category: Signaling pathways. Alternative Names: BM15075. CAS No. 41859-67-0. Pack Sizes: 10 mM * 1 mL in DMSO; 100 mg. Product ID: HY-B0637. | |
| Bezisterim | Bezisterim (HE 3286; NE-3107) is a synthetic derivative of a natural anti-inflammatory steroid, β-AET. Bezisterim is an orally active partial NF-κB inhibitor. HE3286 reduces proinflammatory signals, including IL-6 and matrix metallopeptidase 3. Bezisterim freely penetrates the blood brain barrier in mice. Bezisterim can be used for the research of the ulcerative colitis, arthritis, experimental autoimmune encephalomyelitis[1][2][3]. Bezisterim is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups. Uses: Scientific research. Category: Signaling pathways. Alternative Names: HE 3286; NE-3107. CAS No. 1001100-69-1. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-108039. | |
| Bezlotoxumab | Bezlotoxumab (BLA761046; MBL-CDB1; MDX-1388) is a fully humanized IgG1/kappa monoclonal antibody directed against Clostridium difficile toxin B. Bezlotoxumab mediates the early reconstitution of gut microbiota to reduce the risk of recurrent Clostridium difficile infection (CDI). Bezlotoxumab can be used for the study of recurrent Clostridium difficile infection prevention[1][2][3]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: BLA761046; MBL-CDB1; MDX-1388. CAS No. 1246264-45-8. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-P9929. | |
| Bezuclastinib | Bezuclastinib (CGT9486) is an orally active, highly selective tyrosine kinase inhibitor with potent activity against KIT D816V. Bezuclastinib can be used for the research of nonadvanced systemic mastocytosis (NonAdvSM)[1]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: CGT9486; PLX 9486. CAS No. 1616385-51-3. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-145557. | |
| BF-168 | BF-168, a candidate probe for PET, is found to specifically recognize both neuritic and diffuse plaques, with a Ki of 6.4 nM for Aβ1-42. Uses: Scientific research. Category: Signaling pathways. CAS No. 634911-47-0. Pack Sizes: 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-112830. | |
| BF-170 | BF-170 is a selective tau fibril binding agent with an EC50 of 221 nM. It exhibits good blood-brain barrier permeability, and after intravenous injection in mice, the concentration in brain tissue reaches 9.1% ID/g within 2 minutes (with a brain clearance rate of 0.25% ID/g after 30 minutes). BF-170 can be used as a probe for tau protein pathology imaging in Alzheimer's disease (AD). It plays an important role in early-stage AD research and holds potential for imaging studies of tau-related neurodegenerative diseases[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 22191-97-5. Pack Sizes: 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-W338446. | |
| BF738735 | BF738735 is a phosphatidylinositol 4-kinase III beta (PI4KIIIβ) inhibitor with an IC50 of 5.7 nM. Uses: Scientific research. Category: Signaling pathways. CAS No. 1436383-95-7. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg. Product ID: HY-U00426. | |
| bFGF (119-126) | bFGF (119-126) is a ligand of bFGF. The complex formed by bFGF (119-126) and bFGF can bind to FGFR1, while inhibiting the bFGF-FGFR1 interaction, FGFR1 phosphorylation and downstream signaling pathways. Therefore, bFGF (119-126) induces cell apoptosis and inhibits cell proliferation, migration, angiogenesis and metastasis. When conjugated with a carrier, bFGF (119-126) enhances cellular uptake via FGFR-mediated endocytosis and serves as an effective FGFR-targeted ligand. When used in combination with ultrasound and Doxorubicin (HY-15142A), bFGF (119-126) significantly enhances the inhibitory effect on tumors. bFGF (119-126) is applicable to research related to lung cancer, breast cancer, glioblastoma and ovarian cancer[1][2][3]. Uses: Scientific research. Category: Signaling pathways. CAS No. 152051-61-1. Pack Sizes: 5 mg; 10 mg. Product ID: HY-P5321. | |
| BG-JF585 | BG-JF585 is Benzylguanine-conjugated JF585 (HY-131025). Benzylguanine is the substrate for SNAP tags. JF585 is a fluorophore (λabs: 593 nm; λem: 611 nm). Uses: Scientific research. Category: Signaling pathways. Alternative Names: SNAP-JF585. CAS No. 2461569-42-4. Pack Sizes: 500 μg; 1 mg; 5 mg. Product ID: HY-D2929. | |
| BGN3 | BGN3 is a good substrate for the SNAP-tag? and H5 enzymes. The activities of SNAP-tag? and H5 enzymes on BGN3 are reasonable (IC50= 15.6 and 23.5 μM, respectively)[1]. BGN3 is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups. Uses: Scientific research. Category: Signaling pathways. CAS No. 1151762-33-2. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-139162. | |
| BG-NH2 | BG-NH2 is a pharmaceutical intermediate. BG-NH2 is suitable for synthesizing fluorescent SNAP tag substrates to label RNA[1]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: SNAP-NH2. CAS No. 674799-96-3. Pack Sizes: 10 mM * 1 mL in DMSO; 100 mg; 250 mg; 500 mg; 1 g. Product ID: HY-W017776. | |
| BGP-15 | BGP-15 is a PARP inhibitor, with an IC50 and a Ki of 120 and 57 μM, respectively. Uses: Scientific research. Category: Signaling pathways. CAS No. 66611-37-8. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-100828. | |
| BGT1-IN-1 | BGT1-IN-1 (compound 9) is a potent BGT1 inhibitor with IC50 value of 13.9, 58.3 μM for hBGT1, GAT3, respectively. BGT1-IN-1 shows no cytotoxic. BGT1-IN-1 shows neuroprotective activity[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 406947-32-8. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg; 250 mg. Product ID: HY-W033027. | |
| BGT226 | BGT226 (NVP-BGT226) is a PI3K (with IC50s of 4 nM, 63 nM and 38 nM for PI3Kα, PI3Kβ and PI3Kγ)/mTOR dual inhibitor which displays potent growth-inhibitory activity against human head and neck cancer cells[1][2]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: NVP-BGT226. CAS No. 915020-55-2. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-13334A. | |
| BGT226 maleate | BGT226 (NVP-BGT226 maleate) is a PI3K (with IC50s of 4 nM, 63 nM and 38 nM for PI3Kα, PI3Kβ and PI3Kγ) /mTOR dual inhibitor which displays potent growth-inhibitory activity against human head and neck cancer cells[1][2]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: NVP-BGT226 maleate. CAS No. 1245537-68-1. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-13334. | |
| BHPI | BHPI is a nuclear receptor ERα inhibitor. BHPI activates PLCγ and UPR. BHPI has antitumor activity against breast, endometrial, and ovarian cancers[1][2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 56632-39-4. Pack Sizes: 10 mM * 1 mL in DMSO; 2 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg; 1 g. Product ID: HY-12825. | |
| BHQ-1 NHS | BHQ-1 NHS is a quencher and fluorescent dye. BHQ-1 NHS enables direct labeling via fluorescently labeled nucleotides[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 916753-61-2. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-154834. | |
| BHQ-2 NHS | BHQ-2 NHS is a dark quencher with no native emission due to the polyaromatic-azo backbone and a terminal NHS ester. UBHQ-2 NHS has a wide and intense quenching range from 560-670 nm, which makes it useful as an acceptor in fluorescence resonance energy transfer (FRET) applications in conjunction with orange to far-red emitting dyes. The NHS ester can be applied to label the primary amines (-NH2) of proteins, amine-modified oligonucleotides, and other amine-containing molecules. Uses: Scientific research. Category: Signaling pathways. CAS No. 916753-62-3. Pack Sizes: 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-42984. | |
| BI-0115 | BI-0115 is a selective inhibitor of LOX-1 (IC50=5.4 μM) that blocks cellular uptake of oxLDL. BI-0115 binding triggers receptor inhibition by formation of dimers of the homodimeric ligand binding domain[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 4929-23-1. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg. Product ID: HY-23999. | |
| BI 01383298 | BI 01383298, a chemical probe, is a potent inhibitor of the sodium-citrate co-transporter (SLC13A5) that is highly expressed in the liver[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2227549-00-8. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-124738. | |
| BI-113823 | BI-113823 is an orally active, blood-brain barrier-permeable bradykinin B1 receptor antagonist, with a Ki value of 5.3 nM for human receptors and 13.3 nM for rat receptors. BI-113823 reduces inflammation-induced mechanical hyperalgesia, as well as the mechanical sensitivity of peripheral afferent nerves and spinal nociceptive-specific neurons. BI-113823 alleviates liver fibrosis and portal hypertension, and improves survival in chronic liver disease models. BI-113823 inhibits the activities of monocytes, neutrophils and hepatic stellate cells, as well as the PI3K/Akt signaling pathway. BI-113823 can be used in research related to inflammatory pain, liver fibrosis and portal hypertension[1][2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1119282-90-4. Pack Sizes: 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-168906. | |
| BI-1347 | BI-1347 is an orally active, selective and potent CDK8 inhibitor (IC50=1.1 nM). BI-1347 shows anti-tumoral activity[1][2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2163056-91-3. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-120350. | |
| BI-1622 | BI-1622 is an orally active, potent and highly selective HER2 (ERBB2) inhibitor, with an IC50 of 7 nM. BI-1622 shows greater than 25-fold selectivity over EGFR. BI-1622 shows high antitumor efficacy in vivo in xenograft mouse tumor models with engineered H2170 and PC9 cells and had a favorable agent metabolism and pharmacokinetics profile[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2681392-19-6. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-150023. | |
| BI-167107 | BI-167107 is a high affinity, full agonist that binds to the β2 adrenergic receptor (β2AR) with a dissociation constant Kd of 84 pM[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1202235-68-4. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-121251. | |
| BI 224436 | BI 224436 is a novel HIV-1 noncatalytic site integrase inhibitor with EC50 values of less than 15 nM against different HIV-1 laboratory strains. Uses: Scientific research. Category: Signaling pathways. CAS No. 1155419-89-8. Pack Sizes: 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-18595. | |
| BI-2493 | BI-2493 is a structural analogue of BI-2865 and a highly selective and orally active pan-KRAS inhibitor. BI-2493 can attenuate tumor growth. BI-2493 can be used for cancer iseases research[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2937344-16-4. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-153723. | |
| BI 2536 | BI 2536 is a dual PLK1 and BRD4 inhibitor with IC50s of 0.83 and 25 nM, respectively[1]. BI-2536 suppresses IFNB (encoding IFN-β) gene transcription[4]. Uses: Scientific research. Category: Signaling pathways. CAS No. 755038-02-9. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 50 mg; 100 mg; 200 mg; 500 mg; 1 g. Product ID: HY-50698. | |
| BI-2545 | BI-2545, a chemical probe, is a potent autotaxin (ATX) inhibitor that significantly reduces LPA, with IC50s of 2.2 nM and 3.4 nM for human ATX and rat ATX, respectively[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2162961-71-7. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-124772. | |
| BI-2852 | BI-2852 is a KRAS inhibitor for the switch I/II pocket (SI/II-pocket) by structure-based agent design with nanomolar affinity. BI-2852 is mechanistically distinct from covalent KRASG12C inhibitor (binds to switch II pocket) and binds ten-fold more strongly to active KRASG12D versus KRASwt (740 nM vs 7.5 μM). BI-2852 blocks GEF, GAP, and effector interactions with KRAS, leading to inhibition of downstream signaling and an antiproliferative effect in KRAS mutant cells. Uses: Scientific research. Category: Signaling pathways. CAS No. 2375482-51-0. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-126247. | |
| BI-2865 | BI-2865 is a none-covalent pan-KRAS Inhibitor. BI-2865 binds to WT, G12C, G12D, G12V and G13D mutant KRAS with KDs of 6.9, 4.5, 32, 26, 4.3 nM respectively. BI-2865 inhibits the proliferation of G12C, G12D or G12V mutant KRAS expressing BaF3 cells (mean IC50: roughly 140 nM)[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2937327-93-8. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-153724. | |
| BI-3231 | BI 3231, a chemical probe, is a potent and selective hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) inhibitor, with IC50s of 1 and 13 nM for hHSD17B13 and mHSD17B13, respectively. BI 3231 has the potential for the research of nonalcoholic steatohepatitis (NASH) and other liver diseases[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2894848-07-6. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg; 250 mg; 500 mg; 1 g. Product ID: HY-148814. | |
| BI-3406 | BI-3406 (compound I-6) is an orally active, highly potent and selective inhibitor of the interaction between KRAS and Son of Sevenless 1 (SOS1) with an IC50 of 6 nM. BI-3406 potently reduces the formation of GTP-loaded KRAS, and inhibits MAPK pathway signaling. BI-3406 has anticancer activity[1][2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2230836-55-0. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-125817. | |
| BI-3663 | BI-3663 is a highly selective PTK2/FAK PROTAC (DC50=30 nM), with Cereblon ligands to hijack E3 ligases for PTK2 degradation. BI-3663 inhibits PTK2 with an IC50 of 18 nM. BI-3663 is a PROTAC that composes of BI-4464 (HY-124625) linked to Pomalidomide (HY-10984) with a linker[1]. Anti-cancer activity[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2341740-84-7. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-111546. | |
| BI-3802 | BI-3802, a chemical probe, is a highly potent BCL6 degrader and inhibits the Bric-à-brac (BTB) domain of BCL6 with an IC50 of ≤3 nM. BI-3802 induces the polymerization of BCL6 and promotes BCL6 degration depended on E3 ligase SIAH1. BI-3802 has antitumor activity[1][2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2166387-65-9. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-108705. | |
| BI-3812 | BI-3812, a chemical probe, is a highly efficient BCL6 inhibitor that is capable of suppressing the BTB domain of BCL6, with an IC50 value of ≤ 3 nM, exhibiting antitumor activity[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2166387-64-8. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-111381. | |
| BI-4020 | BI-4020 is a fourth-generation, orally active, and non-covalent EGFR tyrosine kinase inhibitor. BI-4020 inhibits not only the triple mutant EGFR del19 T790M C797S variant (IC50=0.2 nM in BaF3 cell lines) but also the double mutant EGFR del19 T790M and primary mutant EGFR del19 (IC50=1 nM). BI-4020 also shows activity against EGFR wt (IC50=190 nM). BI-4020 shows high kinome selectivity and good DMPK properties[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2664214-60-0. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-129550. | |
| BI-4142 | BI-4142 is a potent, highly selective and orally active HER2 inhibitor with an IC50 of 5 nM[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2682003-36-5. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg; 250 mg; 500 mg; 1 g. Product ID: HY-150024. | |
| BI-4394 | BI-4394 (MMP13-IN-3), a chemical probe, is a potent, selective, and orally active MMP-13 inhibitor (IC50=1 nM[1]) for the potential treatment of osteoarthritis[2]. BI-4394 is >1000 selective over other MMPs[1]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: MMP13-IN-3. CAS No. 1222173-37-6. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-124029. | |
| BI-4659 | BI-4659 is a TGFβRI and PDGFRα inhibitor with IC50 values of 19 nM and 99 nM, respectively. BI-4659 inhibits the kinase activities of TGFβRI and PDGFRα, blocks the downstream TGFβRI signaling pathway, and reduces the phosphorylation level of Smad2/3 without altering the expression of TGF-β1. BI-4659 is applicable to research related to pulmonary fibrosis, cancer, and renal ischemia-reperfusion injury[1][2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 894784-05-5. Pack Sizes: 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-171878. | |
| BI-4732 | BI-4732 is an orally active, reversible, ATP-competitive EGFR inhibitor with blood-brain barrier penetration. BI-4732 inhibits the kinase activity of EGFR L858R, T790M and C797S with IC50 values of 1 nM while sparing EGFR wild-type. BI-4732 inhibits EGFR and reduces the phosphorylation of AKT, ERK, and S6K. BI-4732 demonstrates excellent intracranial anti-tumor efficacy in YU-1097 xenograft model harboring EGFR_E19del/T790M/C797S. BI-4732 can be used for the study of non-small cell lung cancer (NSCLC)[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2769715-68-4. Pack Sizes: 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-161275. | |
| BI-4916 | BI-4916 is a proagent of BI-4924. BI-4924 is a NADH/NAD+-competitive PHGDH inhibitor. BI-4916 inhibits cancer cell migration. BI-4916 can be used for cancer, inflammation and infection study[1][2][3]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2244451-48-5. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-126253. | |
| BI-4924 | BI-4924 is a lipophilic, highly plasma protein bound selective phosphoglycerate dehydrogenase (PHGDH) inhibitor (IC50=3 nM) with excellent microsomal, as well as hepatocytic stability. Intracellular trapping of BI-4924 disrupts serine biosynthesis with an IC50 of 2200 nM at 72 h[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2244452-09-1. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-126254. | |
| BI-6015 | BI-6015 is a hepatocyte nuclear factor 4α (HNF4α) antagonist that can inhibit the expression of known HNF4α target genes. BI6015 represses insulin promoter activity through HNF4α antagonism. BI-6015 can be used for the research of cancer and diabetes[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 93987-29-2. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-108469. | |
| BI605906 | BI605906, a chemical probe, is a novel IKKβ inhibitor with an IC50 value of 380 nM when assayed at 0.1 mM ATP. Uses: Scientific research. Category: Signaling pathways. CAS No. 960293-88-3. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-13019. | |
| BI 653048 | BI 653048, a chemical probe, is a selective and orally active nonsteroidal glucocorticoid (GC) agonist with an IC50 value of 55 nM[1]. BI 653048 inhibits CP1A2, CYP2D6, CYP2C9, CYP2C19 and CYP3A4 isoforms activity and reduces affinity for the hERG ion channel (IC50>30 μM)[2]. BI 653048 (Compound 103) is also a HCV NS3 protease inhibitor that can reduce viral loads infected with the hepatitis C virus[3]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1198784-72-3. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-12946. | |
| BI-6901 | BI 6901 is a potent, selective CCR10 antagonist (pIC50=9.0). BI 6901 shows high selectivity over other GPCRs, including a number of other chemokine receptors. BI 6901 is efficacious in the murine DNFB model of contact hypersensitivity and can be used for inflammation research[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2040401-92-9. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-116835. | |
| BI-6C9 | BI-6C9 is a highly specific BH3 interacting domain (Bid) inhibitor, which prevents mitochondrial outer membrane potential (MOMP) and mitochondrial fission, and protects the cells from mitochondrial apoptosis inducing factor (AIF) release and caspase-independent cell death in neurons[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 791835-21-7. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-103661. | |
| BI-7273 | BI-7273 is a selective, and cell-permeable BRD9 inhibitor, with an IC50 and a Kd of 19 and 0.75 nM; also shows high effect on BRD7, with an IC50 and a Kd of 117 nM and 0.3 nM. Uses: Scientific research. Category: Signaling pathways. CAS No. 1883429-21-7. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-100351. | |
| BI-749327 | BI-749327 is a potent, high selectivity and orally bioavailable TRPC6 antagonist, with IC50s of 13 nM, 19 nM and 15 nM for mouse, human and guinea pig TRPC6, respectively. BI-749327 is 85-fold more selective for mouse TRPC6 than TRPC3 and 42-fold versus TRPC7[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2361241-23-6. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-111925. | |
| BI-78D3 | BI-78D3 functions as a substrate competitive inhibitor of JNK, inhibit the JNK kinase activity (IC50=280 nM). Uses: Scientific research. Category: Signaling pathways. CAS No. 883065-90-5. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-10366. | |
| BI-847325 | BI-847325 is an ATP competitive dual inhibitor of MEK and aurora kinases (AK) with IC50 values of 4 and 15 nM for human MEK2 and AK-C, respectively. BI-847325 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups. Uses: Scientific research. Category: Signaling pathways. CAS No. 1207293-36-4. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-18955. | |
| BI8622 | BI8622 is a specific inhibitor of the ubiquitin ligase HUWE1 with an IC50 of 3.1 μM. BI8622 can decrease the protein expression levels of c-myc and glycolytic markers as well as immune modulatory markers after HUWE1 inhibition in triple-negative breast cancer (TNBC) cell lines. BI8622 significantly protects against cisplatin (HY-17394)-induced acute kidney injury (AKI). BI8622 significantly reduces the growth of multiple myeloma (MM) cell lines and induces cell cycle arrest. BI8622 can prevent HUWE1-dependent TTBK2 ubiquitination. BI8622 can be studied in research for various diseases including medulloblastoma, acute kidney injury, breast cancer and MM[1][2][3][4][5]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1875036-74-0. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-120929. | |
| BI8626 | BI8626 is a specific inhibitor of the ubiquitin ligase HUWE1 with an IC50 of 0.9 μM[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1875036-75-1. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg. Product ID: HY-120204. | |
| BI-882370 | BI-882370 is a potent and selective RAF kinase inhibitor that binds to the ATP binding site of the kinase positioned in the DFG-out (inactive) conformation of the BRAF kinase. BI-882370 (BI 882370) inhibits the oncogenic BRAFV600E-mutant, the WT BRAF and CRAF kinases with IC50s of 0.4, 0.8, and 0.6 nM, respectively. BI-882370 also inhibits SRC family kinases[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1392429-79-6. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-107779. | |
| BI-9321 trihydrochloride | BI-9321 trihydrochloride is a potent, selective and cellular active nuclear receptor-binding SET domain 3 (NSD3)-PWWP1 domain antagonist with a Kd value of 166 nM. BI-9321 trihydrochloride is inactive against NSD2-PWWP1 and NSD3-PWWP2. BI-9321 trihydrochloride specifically disrupts histone interactions of the NSD3-PWWP1 domain with an IC50 of 1.2 μM in U2OS cells[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2387510-87-2. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-114208A. | |
| BI-9564 | BI-9564, a chemical probe, is a potent, selective and cell-permeable BRD9/BRD7 bromodomains inhibitor, with IC50s of 75 nM and 3.4 μM and Kds of 14 nM and 239 nM, respectively. BI-9564 has an IC50 of > 100 μM for BET family[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1883429-22-8. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-100352. | |
| BI-9787 | BI-9787 is a zwitterionic inhibitior for ketohexokinase, with an IC50 of 12 and 12.8 nM for hKHK-A and hKHK-C. BI-9787 exhibits good metabolic stability in rat hepatocyte and good pharmacokinetic characteristics in rats[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 3043939-18-7. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-161993. | |
| BI 99179 | BI 99179, a chemical probe, is a potent and selective type I fatty acid synthase (FAS) inhibitor with an IC50 of 79 nM. BI 99179 is a tool compound suitable for the in vivo validation of FAS as a target for lipid metabolism related diseases. BI 99179 exhibits significant exposure (both peripheral and central) upon oral administration in rats[1][2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1291779-76-4. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-16100. | |
| BIA 10-2474 | BIA 10-2474 is an inhibitor of fatty acid amide hydrolase (FAAH) with IC50 values of 50 to 70mg/kg in various rat brain regions. Uses: Scientific research. Category: Signaling pathways. CAS No. 1233855-46-3. Pack Sizes: 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-19740. | |
| Biacetyl monoxime | Biacetyl monoxime (Diacetyl monoxime), a myosin ATPase inhibitor, is a skeletal and cardiac muscle contraction inhibitor. Biacetyl monoxime is also a well-characterized non-competitive inhibitor of chemical and motile activity of skeletal muscle myosin-II. Biacetyl monoxime induces sarcoplasmic reticulum Ca2+ release[1][2][3]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: Diacetyl monoxime; DAM. CAS No. 57-71-6. Pack Sizes: 10 mM * 1 mL in DMSO; 100 mg; 500 mg; 1 g; 5 g; 10 g. Product ID: HY-Y0413. | |
Would you like to list your products on USA Chemical Suppliers?
Our database is helping our users find suppliers everyday.